Drug
Ebastine
Ebastine is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
17%
Ph phase_4
4
67%
Ph phase_2
1
17%
Phase Distribution
0
Early Stage
1
Mid Stage
5
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(3)
Completed(3)
Detailed Status
Completed3
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 44 (66.7%)
Trials by Status
completed350%
recruiting233%
not_yet_recruiting117%
Recent Activity
2 active trials
Showing 5 of 6
not_yet_recruitingphase_4
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
NCT07734766
recruitingphase_3
Ebastine Versus Mebeverine in IBS Patients
NCT05815602
recruitingphase_2
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
NCT07114055
completedphase_4
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
NCT01908465
completedphase_4
Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
NCT01144832
Clinical Trials (6)
Showing 6 of 6 trials
NCT07734766Phase 4
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
NCT05815602Phase 3
Ebastine Versus Mebeverine in IBS Patients
NCT07114055Phase 2
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
NCT01908465Phase 4
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
NCT01144832Phase 4
Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
NCT01940393Phase 4
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6